
1. vaccine. 2016 jun 3;34(26):2976-2981. doi: 10.1016/j.vaccine.2016.03.076. epub
2016 mar 26.

status research development vaccines chikungunya.

smalley c(1), erasmus jh(2), chesson cb(3), beasley dwc(4).

author information: 
(1)experimental pathology graduate program, university texas medical branch,
galveston, tx, usa.
(2)human pathophysiology translational medicine graduate program, university 
of texas medical branch, galveston, tx, usa.
(3)human pathophysiology translational medicine graduate program, university 
of texas medical branch, galveston, tx, usa; sealy center vaccine
development, university texas medical branch, galveston, tx, usa.
(4)department microbiology immunology, university texas medical branch,
galveston, tx, usa; sealy center vaccine development, university texas
medical branch, galveston, tx, usa; world health organization collaborating
center vaccine research, evaluation training emerging infectious
diseases, university texas medical branch, galveston, tx, usa. electronic
address: dwbeasle@utmb.edu.

chikungunya virus (chikv) arthritogenic alphavirus last
decade significantly expanded geographical range caused large
outbreaks human disease around world. although mortality rates associated 
with chikv outbreaks low, acute chronic illnesses caused chikv
represent significant burden disease largely affecting low middle income
countries. report summarizes current status vaccine development for
chikv.

copyright Â© 2016 world health organization. published elsevier ltd.. all
rights reserved.

doi: 10.1016/j.vaccine.2016.03.076 
pmid: 27026149  [indexed medline]

